⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Cannabidiol (CBD)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-06-15 — CBD for Individuals at Risk for Alzheimer’s Disease: Double-blind RCT launching (design/aims only, no readout) in individuals at risk for Alzheimer’s disease, testing CBD against validated AD progression biomarkers plus behavioral, neurocognitive, and clinical measures. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
CBD for Individuals at Risk for Alzheimer's Disease
15-jun-2026
novelty 3
per-area 3
strengthens